title: Screening of anti-mycobacterial compounds in a naturally infected zebrafish larvae model.
abstract: Mycobacterium tuberculosis is a deadly human pathogen that causes the lung disease TB. M. tuberculosis latently infects a third of the world's population, resulting in ∼1.5 million deaths per year. Due to the difficulties and expense of carrying out animal drug trials using M. tuberculosis and rodents, infections of the zebrafish Danio rerio with Mycobacterium marinum have become a useful surrogate. However, the infection methods described to date require specialized equipment and a high level of operator expertise.
  
  
  
  We investigated whether zebrafish larvae could be naturally infected with bioluminescently labelled M. marinum by immersion, and whether infected larvae could be used for rapid screening of anti-mycobacterial compounds using bioluminescence. We used rifampicin and a variety of nitroimidazole-based next-generation and experimental anti-mycobacterial drugs, selected for their wide range of potencies against M. tuberculosis, to validate this model for anti-mycobacterial drug discovery.
  
  
  
  We observed that five of the six treatments (rifampicin, pretomanid, delamanid, SN30488 and SN30527) significantly reduced the bioluminescent signal from M. marinum within naturally infected zebrafish larvae. Importantly, these same five treatments also retarded the growth of M. tuberculosis in vitro. In contrast, only three of the six treatments tested (rifampicin, delamanid and SN30527) retarded the growth of M. marinum in vitro.
  
  
  
  We have demonstrated that zebrafish larvae naturally infected with bioluminescent M. marinum M can be used for the rapid screening of anti-mycobacterial compounds with readily available equipment and limited expertise. The result is an assay that can be carried out by a wide variety of laboratories for minimal cost and without high levels of zebrafish expertise.
authors: Bioluminescent Superbugs Lab, University of Auckland, Auckland, New Zealand.|Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.|Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.
authors: J P
authors: JP
authors: Dalton
authors: Bioluminescent Superbugs Lab, University of Auckland, Auckland, New Zealand.|Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.
authors: B
authors: B
authors: Uy
authors: Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.
authors: K S
authors: KS
authors: Okuda
authors: Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.|Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.
authors: C J
authors: CJ
authors: Hall
authors: Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.|Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.
authors: W A
authors: WA
authors: Denny
authors: Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.|Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.
authors: P S
authors: PS
authors: Crosier
authors: Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.
authors: S
authors: S
authors: Swift
authors: Bioluminescent Superbugs Lab, University of Auckland, Auckland, New Zealand s.wiles@auckland.ac.nz.|Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.|Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.
authors: S
authors: S
authors: Wiles
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000302:isolation & purification* / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D007814:Larva / Q000382:microbiology; D008163:Luminescent Measurements; D019910:Mycobacterium marinum / Q000187:drug effects* / Q000254:growth & development; D009593:Nitroimidazoles / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D013194:Staining and Labeling; D015027:Zebrafish / Q000382:microbiology*
chemical_list: D000995:Antitubercular Agents; D009593:Nitroimidazoles; D012293:Rifampin